NORTH WALES, Pa.--(BUSINESS WIRE)-- We commend the FDA for making the recommendation to approve providing women with increased over-the-counter (OTC) access to Plan B One-Step® and we are disappointed that at this late date, the Department of Health and Human Services has come to a different conclusion. We have not yet received the Complete Response Letter at this time. We will review the letter when we receive it and then determine our next steps.

CONTACT:

Media:
Teva USA
Denise Bradley, 215-591-8974
denise.bradley@tevapharm.com

KEYWORDS:   United States  North America  Pennsylvania

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Other Health  FDA  General Health

MEDIA: